The Ohio State University Wexner Medical Center is a test site for one of the biggest clinical trials testing the effectiveness of an experimental COVID-19 vaccine in humans.
Co-developed by the University of Oxford and biopharmaceutical company AstraZeneca, the vaccine is currently in phase three of testing. Trials at Ohio State will start in September with a two-year commitment.
Results from a large early-stage human trial in the United Kingdom showed the experimental vaccine is safe and produces a strong immune response, producing both antibodies and T-cells, which find and attack virus cells.
Who is eligible for the vaccine trial?
The study is open to the public and seeks a mix of health care workers and those at high risk of exposure, such as teachers, first responders, college students, factory workers and restaurant employees. About 25% of study participants will be age 65 or older.
You may be able to take part in the AZD1222 COVID-19 VACCINE Study if you:
- are 18 years of age or older
- are in good or stable health (you may have an underlying medical condition and still take part, if your disease is stable)
- have an increased risk of getting COVID-19
- do not have a previously confirmed diagnosis of COVID-19
Participants will be randomly assigned (by chance) to receive 2 injections of either the investigational vaccine or placebo. A placebo looks like the investigational vaccine but contains no active vaccine. There is twice as much chance of receiving the investigational vaccine than of receiving placebo.
If you take part, you will be in the study for approximately 2 years and will require up to 10 visits to our study center. Additional visits may be required if you develop symptoms of COVID-19 during the study. Your health will be monitored carefully by a team of doctors and nurses throughout the study. The study injections, health assessments, and medical tests related to the study will be provided at no cost to you.